Literature DB >> 7438553

Leishmania mexicana in C3H mice: BCG and levamisole treatment of established infections.

G F Grimaldi, P L Moriearty, R Hoff.   

Abstract

The effect of BCG and levamisole on the course of established murine leishmaniasis was examined. C3H mice infected subcutaneously in the perinasal region with 10(5) L. mexicana promastigotes produced chronic non-ulcerating, non-healing lesions and demonstrated positive humoral and delayed hypersensitivity responses to leishmanial antigens. Infected animals were treated during months 3-5 of infection with either live BCG or with levamisole. Neither treatment resulted in resolution of lesions or in production of a hyperallergic form of infection; similarly, neither immune responses to leishmanial antigens nor histopathological features of lesions were significantly altered. BCG treatment resulted in accelerated growth of primary leishmanial lesions and in the appearance of metastases in some animals. Levamisole treatment of uninfected animals resulted in low levels of antibodies reacting with promastigote antigens, but not in positive delayed intradermal responses. BCG induced delayed intradermal sensitivity to PPD in both infected and control animals; significantly increased delayed reactions to leishmania, were observed in treated uninfected mice.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438553      PMCID: PMC1537004     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Fusion of host cell secondary lysosomes with the parasitophorous vacuoles of Leishmania mexicana-infected macrophages.

Authors:  J Alexander; K Vickerman
Journal:  J Protozool       Date:  1975-11

2.  Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice.

Authors:  L L Smrkovski; C L Larson
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

3.  Granuloma formation in lymph-nodes.

Authors:  S M Gaafar; J L Turk
Journal:  J Pathol       Date:  1970-01       Impact factor: 7.996

4.  Growth of Trypanosoma cruzi in human heart tissue cells and effects of aminonucleoside of puromycin, trypacidin and aminopterin.

Authors:  W E Gutteridge; J Knowler; J D Coombes
Journal:  J Protozool       Date:  1969-08

5.  Observations on the susceptibility of white mice to infection with Leishmania mexicana following whole-body x-irradiation.

Authors:  J J Shaw; A Voller
Journal:  Ann Trop Med Parasitol       Date:  1968-06

6.  Experimental cutaneous leishmaniasis. II. Effects of immunosuppression and antigenic competition on the course of infection with Leishmania enriettii in the guinea-pig.

Authors:  A D Bryceson; P M Preston; R S Bray; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1972-02       Impact factor: 4.330

7.  The effect of BCG on experimental cutaneous leishmaniasis in mice.

Authors:  J Weintraub; F I Weinbaum
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

8.  Effects of levamisole on in vivo and in vitro murine host response to syngeneic transplantable tumor.

Authors:  I J Fidler; L E Spitler
Journal:  J Natl Cancer Inst       Date:  1975-11       Impact factor: 13.506

9.  Effect of levamisole on Mycobacterium leprae in mice.

Authors:  C C Shepard; R Van Landingham; L L Walker
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

10.  Killing in vitro of Trypanosoma cruzi by macrophages from mice immunized with T. cruzi or BCG, and absence of cross-immunity on challege in vivo.

Authors:  R Hoff
Journal:  J Exp Med       Date:  1975-08-01       Impact factor: 14.307

View more
  2 in total

1.  Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis.

Authors:  A C Smith; V Yardley; J Rhodes; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice.

Authors:  A H Fortier; B A Mock; M S Meltzer; C A Nacy
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.